Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

February 01, 2017   |   News

BIAL sells allergic immunotherapy business

BIAL has reached an agreement with the German company Roxall to sell its allergic immunotherapy business unit, known as BIAL Aristegui, dedicated to the development, production and commercialization of anti-allergic vaccines and diagnostic tests.

This operation includes the commercial areas dedicated to allergology in Spain, Portugal and Italy, which represented 7% of BIAL's global turnover in 2016, as well as the R&D and industrial unit located in Bilbao, involving around 100 employees who will become integrated into Roxall.

Downloads
Press Release
Share